DiaMedica Therapeutics Inc. (DMAC): Price and Financial Metrics

DiaMedica Therapeutics Inc. (DMAC): $1.32

-0.03 (-2.22%)

POWR Rating

Component Grades













Add DMAC to Watchlist
Sign Up

Industry: Biotech



in industry

DMAC Stock Price Chart Interactive Chart >

Price chart for DMAC

DMAC Price/Volume Stats

Current price $1.32 52-week high $3.23
Prev. close $1.35 52-week low $1.12
Day low $1.30 Volume 38,570
Day high $1.33 Avg. volume 38,308
50-day MA $1.46 Dividend yield N/A
200-day MA $1.67 Market Cap 34.90M

DiaMedica Therapeutics Inc. (DMAC) Company Bio

DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

DMAC Latest News Stream

Event/Time News Detail
Loading, please wait...

DMAC Latest Social Stream

Loading social stream, please wait...

View Full DMAC Social Stream

Latest DMAC News From Around the Web

Below are the latest news stories about DIAMEDICA THERAPEUTICS INC that investors may wish to consider to help them evaluate DMAC as an investment opportunity.

We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | December 31, 2022

Insider Buying: The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Independent Director Just Bought 38% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the DiaMedica Therapeutics Inc. ( NASDAQ:DMAC...

Yahoo | December 4, 2022

$1 Million Bet On OmniAb? Check Out These 3 Penny Stocks Insiders Are Buying

The Dow Jones closed lower by around 200 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. DiaMedica Therapeutics The Trade: DiaMedica Therapeutics Inc. (NASDAQ: DMAC ) Director Michael Randall Giuffre bought a total of 67,228 … Full story available on Benzinga.com

Benzinga | December 2, 2022

DiaMedica Therapeutics (DMAC) Investor Presentation - Slideshow (NASDAQ:DMAC)

The following slide deck was published by DiaMedica Therapeutics Inc.

Seeking Alpha | November 23, 2022

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorde

Business Wire | November 9, 2022

Read More 'DMAC' Stories Here

DMAC Price Returns

1-mo -8.97%
3-mo 6.45%
6-mo -23.70%
1-year -52.35%
3-year -71.91%
5-year N/A
YTD -16.46%
2022 -57.64%
2021 -63.21%
2020 109.07%
2019 66.67%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9477 seconds.